ArticleFrontiers in oncology2025
Identification of novel prognostic biomarkers for thyroid cancer by integrated transcriptome analysis of metastasis-associated genes.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- APOC1-Associated VLDL-Pathway Dysregulation in Papillary Thyroid Carcinoma: A Reproducible Cross-Cohort Transcriptomic Signature Associated With the Diagnostic-to-Treatment Interval.Chemical biology & drug design · 2026Article
- Myeloid landscape of BRAF-mutant papillary thyroid cancer and thyroiditis.Endocrine-related cancer · 2026Article
- Exploratory Machine Learning and Omics Integration in the Search for Biomarkers of Papillary Thyroid Cancer.Biology · 2026Article
- Development of a biomimetic thyroid acellular scaffold as a 3D platform for modeling thyroid cancer aggressiveness and drug resistance.Frontiers in bioengineering and biotechnology · 2025Article
- Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Distant metastasis (DM) is the most important prognostic factor affecting the overall survival (OS) of thyroid cancer. The current study aimed to discover prognostic biomarkers to predict thyroid cancer survival, particularly papillary thyroid carcinoma (PTC), the most common subtype of thyroid cancer. Methods: Four RNA sequencing (RNA-Seq) datasets of experimental lung metastasis from four transgenic mouse models of PTC, follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC) were integrated to screen for candidate genes involved in DM. The Cancer Genome Atlas-Thyroid Cancer (TCGA-THCA) dataset was used to validate the candidate genes. Results: A total of 105 upregulated and 25 downregulated differentially expressed genes (DEGs) were identified to be present in all four datasets. Regulation of cytokine production, inflammation, immune checkpoint regulation, and MAPK/ERK cascade were major enriched pathways in metastatic tumor cells. Seven genes were identified whose overexpression was present in 63 of 498 PTC patients (13%) and was associated with poor OS (p < 0.01). Clinically, the seven-gene expression signature was associated with older age at the diagnosis, late stage of tumor, tall cell variant, and higher aneuploidy and hypoxia score. Mutation load was increased in patients with seven-gene expression signature: 26 samples had more than one driver mutation (47%, 26/55). Deep deletions in other chromosomal loci were frequently found in patients with BRAFV600E mutations. In contrast, only 7% of patients without a seven-gene expression signature had more than one driver mutation (24/243). Increased chromosomal instability was also observed in patients with a seven gene expression signature. Conclusion: The seven-gene expression signature is associated with poor prognosis and chromosomal instability. These genes may be useful biomarkers for risk stratification for DM and help decision-making in initial surgical recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.